|
|
| | Elgemtumab Basic information |
| Product Name: | Elgemtumab | | Synonyms: | Elgemtumab;Research Grade Elgemtumab (DHD48401);Research Grade Elgemtumab;Elgemtumab (anti-ERBB3) | | CAS: | 1512559-37-3 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Elgemtumab Structure]() |
| | Elgemtumab Chemical Properties |
| form | Liquid | | color | Colorless to light yellow |
| | Elgemtumab Usage And Synthesis |
| Uses | Elgemtumab(LJM716) is a fully human IgG monoclonal antibody. Elgemtumab can specifically bind to HER3, block ligand-dependent and independent HER3 signal transduction and cell proliferation, and has good anti-tumor potential[1]. | | in vivo | Elgemtumab(LJM716)(i.v., 20 mg/kg,once) can reduce pHER3 by 52% and pAKT by 84% in SCID mice with BT474 breast cancer xenografts; while in BxPC-3 pancreatic xenografts In SCID mice, it resulted in a maximum inhibition of pHER3 of 86% and a maximum inhibition of pAKT of 74%[1].
Elgemtumab (LJM716) (20 mg/kg, every other day, 35 days) slows tumor growth in NSG mice with BT474 breast cancer xenografts[1].
| | References | [1] Andrew P Garner, et al. An antibody that locks HER3 in the inactive conformation inhibits tumor growth driven by HER2 or neuregulin. Cancer Res. 2013 Oct 1;73(19):6024-35. DOI:10.1158/0008-5472.CAN-13-1198 |
| | Elgemtumab Preparation Products And Raw materials |
|